赛默飞世尔(TMO)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 TMO 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q1 2026
Item	Category	Value	YoY
Total revenues	revenue	11.01B	6.18%
Interest income	revenue	233.00M	14.78%
Operating income	profit	1.86B	8.57%
Total costs and operating expenses	cost	9.14B	5.71%
Aggregate	revenue	2.10B	9.05%
Cost of revenues	cost	3.26B	4.35%
Selling, general and administrative expenses	cost	2.18B	4.96%
Research and development expenses	cost	336.00M	-1.75%
Restructuring and other costs	cost	49.00M	-50.00%
Consolidated income before income taxes	profit	1.73B	7.04%
Interest expense, nonoperating	cost	354.00M	16.83%
Other income/(expense)	revenue	9.00M	200.00%
Net income	profit	1.66B	9.60%
Provision for/(benefit from) income taxes	cost	70.00M	-26.32%
Equity in earnings/(losses) of unconsolidated entities	revenue	8.00M	-42.86%
Net income attributable to thermo fisher scientific inc.	profit	1.65B	9.56%
Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest	cost	5.00M	25.00%

Business Breakdown
Segment	Value	YoY
Laboratory Products and Biopharma Services	6.00B	7.00%
Life Sciences Solutions	2.22B	13.56%
Analytical Instruments	1.67B	-0.60%
Specialty Diagnostics	1.12B	-0.53%

Balance Sheet Q1 2026
Item	Category	Value
Accounts receivable, less allowances of $149 and $147	assets	9.20B
Inventories	assets	5.50B
Cash and cash equivalents	assets	3.25B
Other current assets	assets	2.68B
Contract assets, net	assets	1.68B
Short-term investments	assets	2.00M
Total current assets	assets	22.32B
Goodwill	assets	55.19B
Acquisition-related intangible assets, net	assets	19.15B
Property, plant and equipment, net	assets	10.66B
Other assets	assets	5.97B
Segment assets	assets	113.28B
Total equity	liabilities	51.94B
Long-term obligations	liabilities	40.07B
Total current liabilities	liabilities	14.62B
Other long-term liabilities	liabilities	4.42B
Deferred income taxes	liabilities	2.11B
Redeemable noncontrolling interest	liabilities	121.00M
Noncontrolling interests	liabilities	7.00M
Treasury stock, common, value	equity	25.36B
Accumulated other comprehensive income/(loss)	equity	2.50B
Total thermo fisher scientific inc. shareholders’ equity	equity	51.93B
Other accrued expenses	liabilities	3.69B
Accounts payable	liabilities	3.34B
Short-term obligations and current maturities of long-term obligations	liabilities	3.09B
Contract liabilities	liabilities	2.93B
Accrued payroll and employee benefits	liabilities	1.56B
Aggregate	equity	79.79B
Retained earnings	equity	60.63B
Capital in excess of par value	equity	18.71B
Common stock, $1 par value, 1,200,000,000 shares authorized; 445,473,074 and 445,160,301 shares issued	equity	445.00M

Operating Activities – 3M 2026
Item	Value
Net income	1.66B
Amortization of acquisition-related intangible assets	430.00M
Depreciation of property, plant and equipment	306.00M
Other noncash income (expense)	88.00M
Stock-based compensation	83.00M
Deferred income tax expense (benefit)	-258.00M
Increase decrease in operating capital excluding deferred taxes	-1.11B

Investing Activities – 3M 2026
Item	Value
Proceeds from sales and maturities of investments	250.00M
Proceeds from cross-currency interest rate swap interest settlements	96.00M
Proceeds from sale of property, plant and equipment	9.00M
Payments to acquire investments	-14.00M
Payment for (proceeds from) other investing activity	-55.00M
Payments to acquire property, plant, and equipment	-376.00M
Payments to acquire businesses, net of cash acquired	-8.87B

Financing Activities – 3M 2026
Item	Value
Net proceeds from issuance of debt	5.24B
Proceeds from issuance of commercial paper	389.00M
Other financing activities, net	39.00M
Payments of ordinary dividends, common stock	-162.00M
Repayments of long-term debt	-1.41B
Payments for repurchase of common stock	-3.00B

Cash Balance – 3M 2026
Item	Value
Cash and cash equivalents, beginning of period	9.88B
Cash and cash equivalents, end of period	3.28B